Transcription factor activity assays revealed that the new inhibitors effectively blocked the activity of NF-κB, HIF1α, and STAT3 in PDAC tumor cells, with dose-dependent reductions in transcription factor activity observed. This evidence concerns the gene NFKB1 and neoplasm.